Salt‐Inducible Kinase 2‐Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis

Salt‐inducible kinase 2 (SIK2) is a promising target for ovarian cancer therapy due to its critical role in tumorigenesis and progression. Currently available SIK2 inhibitors have shown remarkable therapeutic effects on ovarian cancers in preclinical studies. However, direct administration of the SI...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Yue, Yin, Han, Liu, Xiaoyang, Xie, Jinbing, Zhan, Wenjun, Liang, Gaolin, Shen, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353504/
https://www.ncbi.nlm.nih.gov/pubmed/35618488
http://dx.doi.org/10.1002/advs.202202260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353504/
https://www.ncbi.nlm.nih.gov/pubmed/35618488
http://dx.doi.org/10.1002/advs.202202260

Ejemplares similares